Fusion Pharmaceuticals Operating Income

Fusion Pharmaceuticals (FUSN) currently reports a operating income of $-110M as of March 2024. That compares with $-92M in the prior-year period — down 19.4% year over year. Use the charts on this page to explore Fusion Pharmaceuticals's operating income history and peer comparisons.

Fusion Pharmaceuticals's operating income decreased from $-92M to $-110M — a 19.4% year-over-year decrease (period ending March 2024). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Fusion Pharmaceuticals reported $-110M in operating income as of March 2024. That compares with $-92M in the prior-year period — down 19.4% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current operating income of $-110M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Fusion Pharmaceuticals, and consider following FUSN for alerts when major investors trade the stock.

Fusion Pharmaceuticals is classified in the Healthcare sector. On operating income, it currently shows $-110M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing FUSN with unrelated industries.